MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ymthe.2024.10.023

Медицинская библиотека · Molecular therapy : the journal of the American Society of Gene Therapy · 2024

Reversion of metabolic dysfunction-associated steatohepatitis by skeletal muscle-directed FGF21 gene therapy.

Jimenez Veronica, Sacristan Victor, Jambrina Claudia, Jaen Maria Luisa, Casana Estefania, Muñoz Sergio, Marcó Sara, Molas Maria, Garcia Miquel, Grass Ignasi, León Xavier, Elias Ivet, Ribera Albert, Elias Gemma, Sanchez Victor, Vilà Laia, Casellas Alba, Ferre Tura, Rodó Jordi, Carretero Ana, Pumarola Marti, Navarro Marc, Andaluz Anna, Moll Xavier, Añor Sonia, Franckhauser Sylvie, Vergara Mercedes, Caixàs Assumpta, Bosch Fatima

СтатьяПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

The highly prevalent metabolic dysfunction-associated steatohepatitis (MASH) is associated with liver steatosis, inflammation, and hepatocyte injury, which can lead to fibrosis and may progress to hepatocellular carcinoma and death. New treatment modalities such as gene therapy may be transformative for MASH patients. Here, we describe that one-time intramuscular administration of adeno-associated viral vectors of serotype 1 (AAV1) encoding native fibroblast growth factor 21 (FGF21), a key metabolic regulator, resulted in sustained increased circulating levels of the factor, which mediated long-term (>1 year) MASH and hepatic fibrosis reversion and halted development of liver tumors in obese male and female mouse models. AAV1-FGF21 treatment also counteracted obesity, adiposity, and insulin resistance, which are significant drivers of MASH. Scale-up to large animals successfully resulted in safe skeletal muscle biodistribution and biological activity in key metabolic tissues. Moreover, as a step toward the clinic, circulating FGF21 levels were characterized in obese, insulin-resistant and MASH patients. Overall, these results underscore the potential of the muscle-directed AAV1-FGF21 gene therapy to treat MASH and support its clinical translation.

Для цитирования: Jimenez Veronica, Sacristan Victor, Jambrina Claudia, Jaen Maria Luisa, Casana Estefania, Muñoz Sergio, Marcó Sara, Molas Maria, Garcia Miquel, Grass Ignasi, León Xavier, Elias Ivet, Ribera Albert, Elias Gemma, Sanchez Victor, Vilà Laia, Casellas Alba, Ferre Tura, Rodó Jordi, Carretero Ana, Pumarola Marti, Navarro Marc, Andaluz Anna, Moll Xavier, Añor Sonia, Franckhauser Sylvie, Vergara Mercedes, Caixàs Assumpta, Bosch Fatima. Reversion of metabolic dysfunction-associated steatohepatitis by skeletal muscle-directed FGF21 gene therapy.. Molecular therapy : the journal of the American Society of Gene Therapy. 2024. DOI: 10.1016/j.ymthe.2024.10.023.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.